{"entity":{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","aka":[],"tldr":"Blocking cortisol signalling in tumour cells made chemotherapy work better and extended life in resistant ovarian cancer.","summary":"ROSELLA, also GOG-3073, trial NCT05257408 sponsored by Corcept and published in the Lancet in 2025, showed that blocking cortisol signalling in tumour cells with relacorilant makes nab-paclitaxel chemotherapy work better and extends life in platinum-resistant ovarian cancer. It randomised 381 women with one to three prior lines to relacorilant plus nab-paclitaxel or nab-paclitaxel alone, met its primary progression-free survival endpoint and improved overall survival, leading to FDA approval in the first quarter of 2026 as Lifyorli, the first-in-class glucocorticoid receptor antagonist in oncology. OnCo links it to ovarian cancer, relacorilant, paclitaxel and Corcept Therapeutics, and the record notes it as a chemosensitisation mechanism rather than a new cytotoxic. Whether the approach transfers to other chemotherapy-treated cancers is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT05257408","url":"https://clinicaltrials.gov/study/NCT05257408"}],"tags":[],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["relacorilant","paclitaxel"],"companies":["corcept"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05257408","phase":"3","setting":"Platinum-resistant ovarian cancer, 1-3 prior lines: relacorilant + nab-paclitaxel vs nab-paclitaxel","sponsor":"Corcept","result":"OS 16.0 vs 11.9 months (HR 0.69).","started":"2022-06-29","startedType":"actual","yearReported":2025,"enrolled":381,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Relacorilant + nab-paclitaxel","n":188,"value":6.5},{"name":"Nab-paclitaxel","n":193,"value":5.5}],"hr":0.7,"ci":[0.54,0.91],"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01011-6/fulltext"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Relacorilant + nab-paclitaxel","value":16},{"name":"Nab-paclitaxel","value":11.9}],"hr":0.69,"source":"https://www.targetedonc.com/view/new-approaches-reshape-treatment-for-low-grade-serous-and-resistant-disease"}]},"route":"/trials/rosella/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/"}],"company":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/"}],"paper":[{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","route":"/key-papers/paper-rosella-relacorilant-lancet-2025/"}]}}